Abstract 155P
Background
Increased mean platelet volume (MPV), an early marker of platelet activation has been shown to be associated with the pathophysiology of various cancers. However, studies analyzing the prognostic effect of MPV [Disease free survival (DFS) and Overall survival (OS)] in carcinoma stomach are lacking. This study was done to analyze the effect of MPV on DFS and OS of resectable carcinoma stomach patients.
Methods
Retrospective analysis of the data of 143 consecutively resected gastrectomy patients between 2009- 13 was done. Associations between MPV and Clinicopathological factors were assessed. DFS and OS for 5 years were analyzed using the Kaplan-Meier curve.MPV of 10.5 femtolitres (fl) yielded maximum combined sensitivity and specificity on ROC curve. The area under curve(AUC) for MPV was 0.611. Therefore Preoperative cut-off value of MPV was taken as 10.5 fl. Differences between survival curves were tested for statistical significance using the log-rank test.
Results
Mean OS in the group with preoperative MPV < 10.5 vs > 10.5 was 59.3 vs 41.3 mts (95% CI = 58.81 – 60 vs 37.87 - 44.94; P = <0.0001). Mean OS in the group with postoperative (after one month) of MPV< 10.5 vs > 10.5 was 37.9 vs 29.2 mts (95% CI = 32-43.8vs 27.1- 19.8; P = <0.0001). Mean DFS in the group with preoperative MPV < 10.5 vs > 10.5 was 59.8 mts vs 38.2 mts (95% CI = 59.365-60.26 vs 31.798- 44.732; P = <0.0001). Mean DFS with postoperative (after one month) MPV< 10.5 vs > 10.5 58.0 mts vs 25.9 months (95% CI = 56.629 - 59.4 vs 20.841- 30.959; P = 0.012). These results show that MPV estimation both preoperatively and postoperative has a significant impact on both DFS and OS. And those patients who had increased MPV preoperatively had lower DFS and OS compared to those who had MPV lower at the initial presentation. Also, those patients who had initial high MPV which declined postoperatively after one month also had better DFS and OS compared to those who had persistent elevated MPV.
Conclusions
Hence MPV both preoperative and postoperative (1 month) shows to be a promising predictive factor in resectable carcinoma stomach.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
504P - A single center report for safety and efficacy of CT-707 in Chinese patients with advanced, anaplastic lymphoma kinase-rearranged non-small cell lung cancer or other tumours
Presenter: Peng Song
Session: Poster display session
Resources:
Abstract
519P - Initial results of lung cancer genomic screening project for individualized medicine in Asia: LC-SCRUM-Asia
Presenter: Chih-Hsi Kuo
Session: Poster display session
Resources:
Abstract
521P - A randomized, phase II study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401)
Presenter: Keisuke Baba
Session: Poster display session
Resources:
Abstract
526P - A phase II study of apatinib in patients with recurrent/metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Li Chu
Session: Poster display session
Resources:
Abstract
499P - Prevalence of uncommon epidermal growth factor receptor (EGFR) alterations detected by circulating tumour DNA (ctDNA) in non-small cell lung cancer (NSCLC) patients in Hong Kong
Presenter: Oscar Siu Hong Chan
Session: Poster display session
Resources:
Abstract
489P - Overall survival in patients with EGFRm+ NSCLC receiving sequential afatinib and osimertinib: Updated analysis of the GioTag study
Presenter: Maximilian J. Hochmair
Session: Poster display session
Resources:
Abstract
509P - Second-line treatment after first-line vinorelbine in advanced platinum unfit NSCLC patients: An exploratory analysis of randomized Tempo-Lung trial
Presenter: Andrea Camerini
Session: Poster display session
Resources:
Abstract
500P - Clinico-molecular characteristics of Chinese primary non-small cell lung cancer patients with compound EGFR mutations
Presenter: Jianchun Duan
Session: Poster display session
Resources:
Abstract
527P - A multicenter study of NRG1 fusions in Chinese non-small cell lung cancer patients and response to afatinib using next generation sequencing
Presenter: Xingliang Li
Session: Poster display session
Resources:
Abstract
481P - Updated survival outcomes of the phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small cell lung cancer (KTORG1402)
Presenter: Toshihide Yokoyama
Session: Poster display session
Resources:
Abstract